TABLE 6.

Impact of carbapenem resistance in Acinetobacter spp. on mortality, LOS, and hospital costs

Type of study showing an impact of resistance	Setting	Infection	No. of cases/no. of controls	Parameter	Main findings	Significance (P value or 95% CI)	Reference
Case-control	Tertiary care	Nosocomial	10/10	Mortality	Cases, 34%; controls, 27%	P > 0.05	9
				LOS	Cases, 31.5 days; controls, 13 days	P = 0.02
Case-control	Tertiary care	Burn patients	34/43	Mortality	Cases, 26.5%; controls, 0%	P < 0.01	82
				LOS	Cases, 32.5 days; controls 21 days	P < 0.01
Case-control	Tertiary care	Burn patients	34/183	LOS	Cases, 36.8 days; controls, 25.6 days	P = 0.06	81
				Cost	Cases, $98,575 higher	P < 0.01
Case-control	Tertiary care	BSI	40/40a	Mortality	Cases, 57.5%; controls, 25.7%	P = 0.007	39
Case-control	ICU	Nosocomial infections	34/68a	Mortality	OR,b 3.9	1.4-10.7	61
				LOS	Cases, 30 days longer	11-38 days
Case-control	ICU	Colonization	32/63a	LOS (ICU)	Cases, 19 days longer	5-28 days	61

^aStudies with either matched controls or multivariate analysis, in order to minimize confounding.

^bOR, odds ratio.